1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023

Summary

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

CLL is the most common form of leukemia in the western world, with an average annual incidence of 5.0 per 100,000 population in people of all ages. CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period. The 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period.

GlobalData’s epidemiological forecast for the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM is supported by age- and sex-specific data for incidence and 1- to 5-year relative survival data used for the 5-year diagnosed prevalent cases forecast are supported by country-specific, population-based studies that are nationally representative of the entire population in the respective markets. The diagnosed incident cases of CLL in each of the 6MM were further segmented by Rai stage at diagnosis to provide a more detailed analysis of the patient population, as Rai stage at diagnosis is an important factor for predicting the prognosis and treatment modalities for CLL at different stages.

Scope

- The Chronic lymphocytic leukemia (CLL) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (beginning at 40 years and ending at 80 years and older) and sex. GlobalData epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally, the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM.
- The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global CLL market.
- Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CLL therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023
1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 Incidence 12
3.3.2 Survival from CLL - US and 5EU 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases 19
3.4.4 Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases 21
3.4.5 Forecast Assumptions and Methods, Rai Stage at Diagnosis 22
3.5 Epidemiological Forecast of CLL (2013-2023) 22
3.5.1 Diagnosed Incident Cases of CLL 22
3.5.2 Age-Specific Diagnosed Incident Cases of CLL 24
3.5.3 Sex-Specific Diagnosed Incident Cases of CLL 25
3.5.4 Age-Standardized Diagnosed Incidence of CLL 27
3.5.5 Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis 28
3.5.6 5-Year Diagnosed Prevalent Cases of CLL 29
3.6 Discussion 31
3.6.1 Epidemiological Forecast Insight 31
3.6.2 Limitations of the Analysis 32
3.6.3 Strengths of the Analysis 32
4 Appendix 34
4.1 Bibliography 34
4.2 About the Authors 36
4.2.1 Epidemiologists 36
4.2.2 Reviewers 36
4.2.3 Global Director of Epidemiology and Health Policy 38
4.2.4 Global Head of Healthcare 38
4.3 About GlobalData 39
4.4 About EpiCast 39
4.5 Disclaimer 40

1.1 List of Tables

Table 1: CLL Clinical Stages at Diagnosis 10
Table 2: Risk Factors and Comorbidities for CLL 11
Table 3: Trends in the Age-Adjusted Incidence of CLL in the US, All Ages, 2003-2010 13
Table 4: Trends in the Age-Adjusted Incidence of CLL(Cases per 100,000 Population) in France, All Ages, 1980-2012 14
Table 5: Trends in the 5-Year Relative Survival (%) of CLL in the US and 5EU, Both Sexes, 1993-2009 15
Table 6: Sources of Epidemiological Data Used for the Forecast for CLL Incident and Prevalent Cases, and the Rai Stage at Diagnosis 16
Table 7: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ?40 Years, N, 2013-2023 23
Table 8: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N (Row %), 2013 24
Table 9: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ?40 Years, N (Row %), 2013 26
Table 10: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ?40 Years, N, 2013-2023 30

1.2 List of Figures

Figure 1: 6MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ?40 Years, N, 2013-2023 23
Figure 2: 6MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 2013 25
Figure 3: 6MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ?40 Years, N, 2013 26
Figure 4: 6MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Ages ?40 Years, by Sex, 2013 28
Figure 5: 6MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Ages ?40 Years, N, 2013 29
Figure 6: 6MM, 5-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ?40 Years, N, 2013-2023 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US and South Korea

  • November 2016
    2 pages
  • Cancer  

  • United States  

    South Korea  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.